This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Platinum
DrugBank Accession Number
DB12257
Background

Platinum is under investigation for the treatment of Metastatic Breast Cancer, Non-small Cell Lung Cancer, Gastric Large Cell Neuroendocrine Carcinoma, Colorectal Large Cell Neuroendocrine Carcinoma, and Pancreatic Large Cell Neuroendocrine Carcinoma, among others. Platinum has been investigated for the treatment and supportive care of Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Primary Cancer, Non Small Cell Lung Cancer, and Primary Peritoneal Carcinoma, among others.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 195.084
Monoisotopic: 194.964774449
Chemical Formula
Pt
Synonyms
  • platino

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
ArticaineThe risk or severity of methemoglobinemia can be increased when Platinum is combined with Articaine.
BenzocaineThe risk or severity of methemoglobinemia can be increased when Platinum is combined with Benzocaine.
Benzyl alcoholThe risk or severity of methemoglobinemia can be increased when Platinum is combined with Benzyl alcohol.
BupivacaineThe risk or severity of methemoglobinemia can be increased when Platinum is combined with Bupivacaine.
ButacaineThe risk or severity of methemoglobinemia can be increased when Platinum is combined with Butacaine.
ButambenThe risk or severity of methemoglobinemia can be increased when Platinum is combined with Butamben.
CapsaicinThe risk or severity of methemoglobinemia can be increased when Platinum is combined with Capsaicin.
ChloroprocaineThe risk or severity of methemoglobinemia can be increased when Platinum is combined with Chloroprocaine.
CinchocaineThe risk or severity of methemoglobinemia can be increased when Platinum is combined with Cinchocaine.
CocaineThe risk or severity of methemoglobinemia can be increased when Platinum is combined with Cocaine.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of inorganic compounds known as homogeneous transition metal compounds. These are inorganic compounds containing only metal atoms,with the largest atom being a transition metal atom.
Kingdom
Inorganic compounds
Super Class
Homogeneous metal compounds
Class
Homogeneous transition metal compounds
Sub Class
Not Available
Direct Parent
Homogeneous transition metal compounds
Alternative Parents
Not Available
Substituents
Homogeneous transition metal
Molecular Framework
Not Available
External Descriptors
elemental platinum (CHEBI:33400)
Affected organisms
Not Available

Chemical Identifiers

UNII
49DFR088MY
CAS number
7440-06-4
InChI Key
BASFCYQUMIYNBI-UHFFFAOYSA-N
InChI
InChI=1S/Pt
IUPAC Name
platinum
SMILES
[Pt]

References

General References
Not Available
Human Metabolome Database
HMDB0013671
PubChem Compound
23939
PubChem Substance
347828531
ChemSpider
22381
RxNav
1311280
ChEBI
33364
PharmGKB
PA150595617
Wikipedia
Platinum

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentNon-squamous Non-small-cell Lung Cancer (NSQ NSCLC)1
4Not Yet RecruitingTreatmentNon-Small Cell Lung Cancer (NSCLC)2
4RecruitingTreatmentHemophagocytic Syndrome (HPS) / NK/T-cell Lymphoma1
4Unknown StatusTreatmentNon-Small Cell Lung Cancer (NSCLC)1
3Active Not RecruitingTreatmentAdenocarcinoma of the Cervix / Advanced Vaginal Adenocarcinoma / Advanced Vaginal Adenosquamous Carcinoma / Advanced Vaginal Squamous Cell Carcinoma / Cervical Adenosquamous Cell Carcinoma / Squamous Cell Carcinoma of the Cervix / Stage IB2 Cervical Cancer AJCC v6 and v7 / Stage II Cervical Cancer AJCC v7 / Stage II Vaginal Cancer AJCC v6 and v7 / Stage IIA Cervical Cancer AJCC v7 / Stage IIB Cervical Cancer AJCC v6 and v7 / Stage III Vaginal Cancer AJCC v6 and v7 / Stage IIIB Cervical Cancer AJCC v6 and v7 / Stage IV Vaginal Cancer AJCC v6 and v7 / Stage IVA Cervical Cancer AJCC v6 and v7 / Stage IVA Vaginal Cancer AJCC v6 and v7 / Unresectable Vaginal Carcinoma / Vaginal Adenocarcinoma / Vaginal Adenosquamous Carcinoma / Vaginal Carcinoma / Vaginal Squamous Cell Carcinoma, Not Otherwise Specified1
3Active Not RecruitingTreatmentAdenocarcinoma of the Cervix / Cervical Adenosquamous Cell Carcinoma / Cervical Squamous Cell Carcinoma, Not Otherwise Specified / Stage I Cervical Cancer AJCC v6 and v7 / Stage IA Cervical Cancer AJCC v6 and v7 / Stage IB Cervical Cancer AJCC v6 and v7 / Stage IIA Cervical Cancer AJCC v71
3Active Not RecruitingTreatmentAnaplastic Ependymoma / Cellular Ependymoma / Clear Cell Ependymoma / Ependymoma / Papillary Ependymoma1
3Active Not RecruitingTreatmentAnaplastic Medulloblastoma / Medulloblastomas1
3Active Not RecruitingTreatmentAntineoplastic Agents1
3Active Not RecruitingTreatmentChildhood Atypical Teratoid/Rhabdoid Tumor1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP0.03Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count0Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area0 Å2Chemaxon
Rotatable Bond Count0Chemaxon
Refractivity0 m3·mol-1Chemaxon
Polarizability1.78 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at October 20, 2016 21:44 / Updated at June 12, 2020 16:53